Blarcamesine appeared to slow the decline of cognition and functional capacity for people with Alzheimer’s disease in a ...

In early-stage Alzheimer's, changes in abilities or behavior may be minor and only noticeable to family and close friends. Some symptoms typify this stage.

Nearly half the Alzheimer's disease patients treated with TrueBinding's investigational therapy TB006 showed cognitive improvement signs.

Foralumab, an investigational nasal spray being developed by Tiziana Life Sciences, has been cleared by the U.S. Food and Drug Administration (FDA) for expanded use to treat moderate Alzheimer’s ...

Anavex is preparing meetings with regulatory authorities in the U.S., Europe, and Asia-Pacific to discuss Anavex 2-73’s potential approval.

For the first time, the beneficial effects of pure maple syrup were included in the natural products that protect brain cells against the neural damage found in patients with Alzheimer’s disease. Dr.

Treatment with lecanemab (BAN2401), an experimental amyloid-targeting antibody, significantly slowed the progression of dementia symptoms among people with early Alzheimer’s disease in the Phase 3 ...

Moderate stage Alzheimer's is the second and longest stage of this brain disease, likely marked by increased forgetfulness, confusion, and trouble speaking.

Columnist Ray Burow clarifies some common misconceptions about Alzheimer's disease, particularly that it's a type of mental illness.

Blazing through a magazine or newspaper is an activity most of us take for granted. However, someone with cognitive impairment may have difficulty devouring content. Deciphering small print and ...

The small snacks available in the U.S. and U.K. encourage people with Alzheimer's and dementia to increase their water intake.

On-demand treatment with BXCL501 was found to significantly ease episodes of agitation for Alzheimer's patients in a Phase 3 clinical trial.